28.05.2010:
Further Details regarding Reimbursement Procedure for Former Minority Shareholders of Zentiva N.V.
Prague, May 28, 2010 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY)
Further Details regarding Reimbursement Procedure for Former Minority Shareholders of Zentiva N.V. The former minority shareholders of Zentiva N.V. are now in a position to obtain the reimbursement for their shares which were subject to the squeeze-out procedure.
The first step that each former Zentiva N.V. shareholder should take in connection with the reimbursement process is to contact its broker that was involved in the purchase of such shareholder’s shares in Zentiva N.V. The broker will be able to provide necessary identification details related to the shareholder and its purchase of Zentiva N.V. shares. This information is needed before any claim for reimbursement can be processed. It is recommended that each former shareholder contacts its broker as soon as possible. The broker should then contact the Central Securities Depository in Prague (Centrální depozitář cenných papírů, a.s.), which is managing the reimbursements that are being made by the Dutch Consignment Office.
If, however, the former Zentiva N.V. shares were obtained as part of an inheritance, the shareholder will have to present the relevant inheritance-related documents issued by the public notary (such as the will with the legal validity clause).
Once the shareholder or its broker has provided the Central Securities Depositary in Prague with the information needed to support the reimbursement claim it should take about two months for the reimbursement to be processed and the relevant funds to be credited to the relevant account of the shareholder.
Specific details of the above steps need to be discussed with the broker.
Important links:
Reimbursement - English Version (PDF file, 19 kB)
Reimbursement - Czech Version (PDF file, 26 kB)
IMPORTANT NOTICES
This document is published in English and Czech version, however, only its English version should be considered the official one. Czech version is published solely for information purposes, and no representation is made and no warranty is given as to the accuracy of the Czech tranlation. Should there be any difference between the English and Czech version of this document, the English version shall always prevail.
NOTE FOR EDITORS
Zentiva, part of the sanofi-aventis Group, is a leading provider of modern, high quality affordable medicines in Central and Eastern Europe. Zentiva is headquartered in Prague, Czech Republic.
CONTACT
Vera Kudynova
Communication Manager, Zentiva
Vera.Kudynova@zentiva.cz
Tel. +420 267 242 312
|